candesartan cilexetil has been researched along with deoxyguanosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, A; Morito, N; Ojima, M; Okamura, M; Shimohata, H; Takahashi, S; Yamagata, K; Yoh, K | 1 |
| Dorjsuren, D; Egli, M; Eoff, RL; Jadhav, A; Lloyd, RS; Maloney, DJ; Simeonov, A; Yamanaka, K | 1 |
2 other study(ies) available for candesartan cilexetil and deoxyguanosine
| Article | Year |
|---|---|
A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Deoxyguanosine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Kidney; Maf Transcription Factors, Large; MafK Transcription Factor; Male; Mice; Mice, Transgenic; Nephrectomy; Tetrazoles | 2012 |
A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.
Topics: Acrolein; Benzimidazoles; Biphenyl Compounds; Cell Line, Transformed; Cell Survival; Deoxyguanosine; DNA; DNA Adducts; DNA Damage; DNA Repair; DNA-Directed DNA Polymerase; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Indoles; Nucleic Acid Synthesis Inhibitors; Small Molecule Libraries; Terpenes; Tetrazoles; Ultraviolet Rays | 2012 |